Search - tctmd.com

Displaying 81 - 100 of 225

Sort: Relevancy | Date

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

News Conference News AHA 2021

Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data

Yael L. Maxwell

November 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

October 2021 News Roundup

News Opinion CV Team Dispatch

October 2021 News Roundup

October 01, 2021

Women Stand to Gain the Most From Standardized STEMI Protocols

News Daily News

Women Stand to Gain the Most From Standardized STEMI Protocols

Michael O'Riordan

September 30, 2021

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

News Features

When the Time Comes to Stop Oral Anticoagulation: Options and Obstacles

September 28, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Long-term Anticoagulation After Unprovoked VTE: New Insights

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

September 13, 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

September 02, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

News Daily News

Largest Study of VITT After COVID-19 Vaccination Digs Into Lab, Clinical Features

August 11, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

New CV Surgery Guidelines Shift Focus to ‘Blood Management’

News Daily News

CV Surgery Societies Urge Shift to ‘Blood Management’

Yael L. Maxwell

June 30, 2021

FDA Approves Dabigatran for VTE in Children

News Daily News

FDA Approves Dabigatran for VTE in Children

June 22, 2021

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

News Daily News

Anticoagulation Use Quickly Rose to Meet COVID-19 Need

June 14, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

May 2021 News Roundup

News Opinion CV Team Dispatch

May 2021 News Roundup

May 01, 2021

AHA/ASA Offers Advice on Rare Blood Clots Seen After Vaccines for COVID-19

News Daily News

AHA/ASA Offers Advice on Rare Blood Clots Seen After Vaccines for COVID-19

April 30, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.